Phase 3 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People with a performance status score of 0 or 1 on the ECOG scale, meaning they are fully active or have only minor limitations in physical activity (confirm with trial site)
- People whose breast cancer has been confirmed by laboratory testing to be invasive ductal carcinoma, no specific type (NOS)
- People whose cancer has tested negative for oestrogen receptors (ER), progesterone receptors (PR), and HER2 — a combination sometimes called "triple-negative" breast cancer
- People who have not yet received any treatment after their cancer has come back or spread to other parts of the body
- People who have at least one tumour or lesion that can be measured on a scan, according to standard medical criteria
- People whose blood test shows a specific ratio of immune cells (neutrophils to lymphocytes) of 2 or above
- People whose heart, kidneys, liver, and bone marrow are all functioning at an adequate level, including a heart pumping function of at least 45% on an echocardiogram
- People who are willing and able to follow the study requirements
- People who have given written, signed consent to participate
Who may not be able to join:
- People who are pregnant or breastfeeding
- People who have a confirmed BRCA gene mutation, or whose cancer tests positive for PD-L1, or shows signs of a specific type of genetic instability known as MSI-H or mismatch repair deficiency (dMMR)
- People who are currently receiving or plan to receive other biological therapies or immunotherapy treatments
- People who have other medical conditions that are not well controlled
- People who have signs of an active infection, whether recent or ongoing
- People who have heart, kidney, liver, or bone marrow problems that do not meet the required function levels (confirm with trial site)
- People who currently have another cancer, or have been diagnosed with a different cancer within the past five years
- People who have had a serious allergic reaction to the antibiotic moxifloxacin
- People who are unable or unwilling to follow the requirements of the study program
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Zhong-yu Yuan, M.D., Sun Yat-sen University
Phone: 862087342794
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
progression-free survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.